JP2024510666A5 - - Google Patents
Info
- Publication number
- JP2024510666A5 JP2024510666A5 JP2023557691A JP2023557691A JP2024510666A5 JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5 JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- composition according
- talazoparib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165723P | 2021-03-24 | 2021-03-24 | |
| US63/165,723 | 2021-03-24 | ||
| US202163282163P | 2021-11-22 | 2021-11-22 | |
| US63/282,163 | 2021-11-22 | ||
| US202263317368P | 2022-03-07 | 2022-03-07 | |
| US63/317,368 | 2022-03-07 | ||
| PCT/IB2022/052536 WO2022200982A1 (en) | 2021-03-24 | 2022-03-21 | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510666A JP2024510666A (ja) | 2024-03-08 |
| JP2024510666A5 true JP2024510666A5 (cg-RX-API-DMAC7.html) | 2025-03-31 |
Family
ID=80952181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557691A Pending JP2024510666A (ja) | 2021-03-24 | 2022-03-21 | Ddr遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240180906A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313034A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510666A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230159510A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022244439A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023018906A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214316A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011294A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022200982A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| BRPI0709771B1 (pt) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| JP2012518661A (ja) | 2009-02-24 | 2012-08-16 | メディベイション プロステイト セラピューティクス, インコーポレイテッド | 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物 |
| EP2416657A4 (en) | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| MX340319B (es) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| CN103282365B (zh) | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 |
| EP3066084A1 (en) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| EA201992430A1 (ru) * | 2017-04-13 | 2020-02-28 | Янссен Фармацевтика Нв | Комбинированная терапия рака предстательной железы |
| AU2018347331A1 (en) * | 2017-10-13 | 2020-04-09 | Merck Patent Gmbh | Combination of a PARP inhibitor and a PD-1 axis binding antagonist |
| US20210355223A1 (en) * | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
-
2022
- 2022-03-21 EP EP22713055.6A patent/EP4313034A1/en active Pending
- 2022-03-21 WO PCT/IB2022/052536 patent/WO2022200982A1/en not_active Ceased
- 2022-03-21 CA CA3214316A patent/CA3214316A1/en active Pending
- 2022-03-21 JP JP2023557691A patent/JP2024510666A/ja active Pending
- 2022-03-21 AU AU2022244439A patent/AU2022244439A1/en not_active Abandoned
- 2022-03-21 KR KR1020237035680A patent/KR20230159510A/ko active Pending
- 2022-03-21 BR BR112023018906A patent/BR112023018906A2/pt unknown
- 2022-03-21 MX MX2023011294A patent/MX2023011294A/es unknown
- 2022-03-21 US US18/283,634 patent/US20240180906A1/en active Pending
-
2025
- 2025-07-30 AU AU2025210784A patent/AU2025210784A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230103007A1 (en) | Combination therapy for treating abnormal cell growth | |
| US20230321097A1 (en) | Methods and compositions for treating abnormal cell growth | |
| CN103945849B (zh) | 癌症的联合治疗 | |
| US20230201198A1 (en) | Methods of treating abnormal cell growth | |
| JP2022510410A5 (cg-RX-API-DMAC7.html) | ||
| JP2002535249A (ja) | 腫瘍を治療する放射線療法及びcox−2阻害剤の組合せ療法。 | |
| AU2018380174A1 (en) | Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| WO2019094053A1 (en) | Disulfiram and copper salt dosing regimen | |
| IL319922A (en) | Combination of TALAZOPARIB and ENZALUTAMIDE in the treatment of metastatic castration-resistant prostate cancer | |
| JP2024502446A5 (cg-RX-API-DMAC7.html) | ||
| CN120659606A (zh) | 治疗转移性去势抵抗性前列腺癌的他拉唑帕尼及恩杂鲁胺的组合 | |
| JP2022543679A5 (cg-RX-API-DMAC7.html) | ||
| US11000518B2 (en) | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer | |
| WO2007108272A1 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
| Arnott | The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma | |
| JP2025511402A5 (cg-RX-API-DMAC7.html) | ||
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| WO2020057536A1 (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| CN116322690A (zh) | 组合的药物抗癌疗法 | |
| US20260041676A1 (en) | Combination Therapy | |
| CN110613713B (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 | |
| TW202448458A (zh) | 雌激素受體降解劑與akt抑制劑之組合 | |
| WO2019174590A1 (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 |